newsfilter
← Latest News
PR Newswire·

Synaptogenix Responds to FDA Approval of Aducanumab

NEW YORK, June 7, 2021 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today issued a statement following the announced FDA approval of Biogen's new